Established in 1980 in the UAE, Julphar is one of the largest pharmaceutical manufacturers in the Middle East and North Africa (MENA) and sells its products in over 40 countries.
FACTOIDS
- Julphar is one of the largest pharmaceutical manufacturers in the Middle East and North Africa
- Their commitment to quality has earned them ISO 9001 and ISO 14001 certifications
- With a focus on innovation in biotechnology, Julphar launched a $150 million manufacturing facility
BLAZE TO BRILLIANCE
The decision to create Julphar came at a time when the UAE was making the transition from herbal medicines to conventional medicines and the founders of Julphar wanted to invest in a sector which would generate long-term value for the Emirates. It currently operates 12 internationally certified manufacturing facilities globally, produces over a million boxes of medicines daily and holds 3,483 product registration certificates.
FAITH FACTOR
Julphar employs approximately 3000 personnel around the world and registered sales revenues of AED 1.36 billion in the year ending 2013, up by 15.4 per cent Year-on-Year (YoY). The sales during the year were driven by the private market sales which saw a Y-o-Y growth of 19.4 per cent. Emerging markets remain a key priority for sustainable growth as Julphar’s Middle Eastern roots allow it to reach difficult markets in a timely manner.
ENGAGEMENT THAT ENTHRALS
Julphar maintains a diverse product portfolio which targets major therapeutic segments including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management. Eleven of the Julphar facilities are based in the UAE and cover production areas including tablets, syrups and suspensions. In 2013, Julphar launched a twelfth manufacturing facility in Ethiopia, as part of its ongoing international expansion strategy.
INNOVEDGE
With a focus on innovation in biotechnology, Julphar launched a $150 million manufacturing facility for producing raw material needed for biosimilar products. Today, this facility is the only plant in the MENA region that produces insulin using insulin crystals derived from r-DNA technology.
BRAND PROMISE
With over 800 products in various dosage forms and more in the pipeline, Julphar is a stellar example of one of the UAE’s local businesses making an impact on the global stage. Also, their commitment to quality has earned them ISO 9001 and ISO 14001 certifications. These practices and approvals ensure that an effective and well-documented framework is always in place and is strictly followed, not only for the manufacturing of products but also for the effective use of resources and reduction of wastes.
